Please enable Javascript on your browser for a better experience.
The Metabolic Syndrome & Glucose Control Panel evaluates key biomarkers—fasting glucose, insulin, lipids, and related metrics—to assess insulin resistance, glucose dysregulation, and cardiometabolic risk. This integrated panel helps clinicians identify metabolic syndrome early, monitor glycemic control, and guide interventions to reduce progression to type 2 diabetes and cardiovascular disease.
The Triglyceride Driver Identification Panel combines triglycerides with apolipoprotein C-III testing to reveal not just elevated fat levels, but the underlying regulatory drivers. By identifying impaired triglyceride breakdown and clearance, this advanced blood panel provides deeper insight into cardiometabolic risk beyond standard lipid testing and supports more precise evaluation of persistent or unexplained triglyceride elevation.
ApoC-III Triglyceride Driver Panel
The IGF Binding Protein 1 (IGFBP-1) Test measures IGFBP-1, a protein that regulates insulin-like growth factor (IGF) activity and reflects insulin sensitivity. Abnormal levels may indicate insulin resistance, type 2 diabetes risk, or metabolic syndrome. Doctors use this test to evaluate glucose regulation, investigate metabolic disorders, and support early detection of endocrine imbalances that affect growth, energy balance, and long-term health.
The Insulin Response to Glucose Test, 5 Specimens evaluates insulin secretion at fasting and multiple post-glucose solution intervals. This expanded assessment highlights beta-cell function, insulin sensitivity, and abnormalities in carbohydrate metabolism. Results offer valuable information on how the body clears glucose and help identify insulin resistance, metabolic dysfunction, and diabetes-related risks.
The Leptin Test measures leptin hormone levels in blood to evaluate metabolism, appetite regulation, and body fat balance. Abnormal levels may indicate obesity, metabolic syndrome, insulin resistance, or leptin deficiency. Doctors use this test to assess unexplained weight gain, difficulty losing weight, or potential endocrine disorders. It also supports research on energy balance, fertility, and overall metabolic health management.
The Cardio IQ™ Insulin Test measures fasting insulin levels in the blood to help evaluate insulin resistance, metabolic health, and risk for conditions like type 2 diabetes and cardiovascular disease. It provides insight into how the body regulates blood sugar and supports personalized risk assessment and treatment planning.
The Testosterone Free and Total Test measures total testosterone and free, bioavailable testosterone in blood for both men and women. It helps diagnose hormone imbalance, infertility, low libido, erectile dysfunction in men, irregular periods, or PCOS in women. Doctors also order it to assess fatigue, mood changes, or muscle weakness and to monitor hormone therapy. This test provides key insight into reproductive, endocrine, and overall metabolic health.
The AALP Apolipoprotein C3 Test measures apolipoprotein C-III, a key regulator of triglyceride metabolism and lipoprotein clearance. Elevated ApoC-III levels are linked to impaired triglyceride breakdown, atherogenic remnant particles, and increased cardiometabolic risk. This advanced blood test provides deeper insight beyond standard lipid panels, helping identify hidden cardiovascular and metabolic risk and supporting more personalized lipid health assessment.
The Cardio IQ™ Diabetes and ASCVD Risk Panel with Scores measures advanced cardiovascular and metabolic markers to evaluate risk for atherosclerotic cardiovascular disease and type 2 diabetes. This panel includes lipid analysis, glucose-related biomarkers, and inflammation indicators, helping assess cardiometabolic health. Results provide clinicians with detailed scoring to identify patterns that may influence prevention and long-term disease management.
The NMR Lipoprotein Fractionation Test uses nuclear magnetic resonance to measure particle size and concentration of LDL, HDL, and VLDL cholesterol. Unlike a standard lipid panel, it provides detailed information on lipoprotein subfractions linked to cardiovascular risk. Doctors use this test to assess heart disease risk, guide cholesterol management, and monitor therapy effectiveness. It offers deeper insight into lipid metabolism and cardiovascular health.
The IGF Binding Protein 3 (IGFBP-3) Test measures IGFBP-3, the primary carrier of insulin-like growth factor 1 (IGF-1), to evaluate growth hormone activity. Abnormal levels may indicate growth disorders, pituitary dysfunction, or nutritional problems. Doctors use this test with IGF-1 to assess short stature, delayed or rapid growth, and monitor therapy for growth hormone deficiency or excess, supporting accurate diagnosis and treatment.
The Insulin Response to Glucose Test, 2 Specimens evaluates insulin secretion by comparing fasting levels with those measured after drinking a glucose solution. This test helps identify impaired insulin sensitivity, abnormal glucose regulation, and early metabolic dysfunction. It provides valuable information on beta-cell function, carbohydrate metabolism, and risk of developing prediabetes or diabetes.
The Electrolyte Panel Test measures sodium, potassium, chloride, and carbon dioxide in blood to evaluate fluid balance, kidney function, and acid-base status. Abnormal results may indicate dehydration, kidney disease, adrenal disorders, or respiratory issues. Doctors use this test to investigate symptoms such as weakness, confusion, or irregular heartbeat. Results provide essential insight into electrolyte balance, hydration, and overall metabolic and organ health.
